FindTrial
Sign In

IPI-549 (eganelisib)

DRUG3 trials

Sponsors

Infinity Pharmaceuticals, Inc.

Conditions

Adrenocortical Carcinoma (Part G)Advanced CancerAdvanced Solid Tumors (Part A/B/C/D)Bladder CancerBreast CancerHigh-circulating Myeloid-derived Suppressor Cells (Part H)Melanoma (Part E)Mesothelioma (Part G)

Phase 1

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
NCT02637531
Infinity Pharmaceuticals, Inc.Adrenocortical Carcinoma (Part G), Advanced Solid Tumors (Part A/B/C/D), High-circulating Myeloid-derived Suppressor Cells (Part H) +5
Start: 2015-12-31End: 2022-12-31Updated: 2022-04-04

Phase 2

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
NCT03961698
Infinity Pharmaceuticals, Inc.Breast Cancer, Renal Cell Carcinoma
Start: 2019-12-17End: 2023-08-31Updated: 2023-08-14
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
CompletedNCT03980041
Infinity Pharmaceuticals, Inc.Advanced Cancer, Bladder Cancer, Solid Tumor +1
Start: 2019-09-25End: 2022-11-15Updated: 2022-11-25

Related Papers

Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment
Journal for ImmunoTherapy of Cancer2024-08-0143 citations
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Clinical Cancer Research2023-03-3167 citations
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.
2021-08-0136 citations
Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma.
Journal of Clinical Oncology2021-02-2016 citations
434 Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab
Regular and Young Investigator Award Abstracts2020-11-0110 citations
352 Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab
Regular and Young Investigator Award Abstracts2020-11-019 citations
Abstract IA26: Reprogramming tumor-associated macrophages by targeting PI3K-gamma with IPI-549
Molecular Cancer Research2020-10-01
Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.
Journal of Clinical Oncology2018-05-2055 citations
Abstract CT089: IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors
Cancer Research2017-07-0111 citations
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
2016-11-09681 citations
Abstract B032: The PI3K-γ inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment
Cancer Immunology Research2016-10-314 citations
Abstract B070: IPI-549-01: A Phase I/Ib first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors
Cancer Immunology Research2016-10-312 citations
IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors.
Journal of Clinical Oncology2016-05-206 citations